Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study

Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A. Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S. Abramson

Open source

DOI: 10.1200/jco-25-00399
Published: 2025-08-20
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-25-00399,
  title = {Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study},
  author = {Manali Kamdar and Scott R. Solomon and Jon Arnason and Patrick B. Johnston and Bertram Glass and Veronika Bachanova and Sami Ibrahimi and Stephan Mielke and Pim Mutsaers and Francisco Hernandez-Ilizaliturri and Koji Izutsu and Franck Morschhauser and Matthew Lunning and Victor A. Chow and Sandrine Montheard and Josu Santamaria and Silvia Colicino and Ken Ogasawara and Lara Stepan and Fei Fei Liu and Jeremy S. Abramson},
  year = {2025},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco-25-00399},
  url = {https://doi.org/10.1200/jco-25-00399}
}

RIS

TY  - JOUR
TI  - Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
AU  - Manali Kamdar
AU  - Scott R. Solomon
AU  - Jon Arnason
AU  - Patrick B. Johnston
AU  - Bertram Glass
AU  - Veronika Bachanova
AU  - Sami Ibrahimi
AU  - Stephan Mielke
AU  - Pim Mutsaers
AU  - Francisco Hernandez-Ilizaliturri
AU  - Koji Izutsu
AU  - Franck Morschhauser
AU  - Matthew Lunning
AU  - Victor A. Chow
AU  - Sandrine Montheard
AU  - Josu Santamaria
AU  - Silvia Colicino
AU  - Ken Ogasawara
AU  - Lara Stepan
AU  - Fei Fei Liu
AU  - Jeremy S. Abramson
PY  - 2025
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco-25-00399
UR  - https://doi.org/10.1200/jco-25-00399
ER  -

APA

Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., Izutsu, K., Morschhauser, F., Lunning, M., Chow, V. A., Montheard, S., Santamaria, J., Colicino, S., Ogasawara, K., Stepan, L., Liu, F. F., & Abramson, J. S. (2025). Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00399

Source records

crossref · retrieved 2026-09-27T05:00:37.768Z